Increase the Identification of Patients Who may be Eligible for Clinical Trials

<table>
<thead>
<tr>
<th>Problem Statement</th>
<th>Root Causes</th>
</tr>
</thead>
</table>
| Patients with advanced lung cancer are not being referred for clinical trial opportunities | • Patients may have misconceptions about clinical trials  
• Lack of awareness about open clinical trials  
• Oncologists may be reluctant to refer patients  
• Lack of an on-site clinical trial coordinator who can facilitate referrals |

Begin with the following patient lists:
• Patients with stages III and IV NSCLC from the last 6 months of 2019 (or any defined time period)

Baseline assessment:
• Proportion of all patients with stages III and IV NSCLC who were referred for clinical trials

Exploratory questions:
• What factors lead oncologists to refer patients for clinical trials?  
• How many open clinical trials are currently available for patients with stages III and IV NSCLC?  
• What are the administrative and financial barriers that prevent patients from being referred for clinical trials?  
• What partnerships have we explored with academic medical centers?
Discuss causes and effects:

Aim Statement (example):

- Over the next <xx> months, we will increase clinical trial referrals by <xx%> among patients with stage III or IV NSCLC.

Potential Solutions

- Develop partnerships with local academic medical centers
- Review and discuss open clinical trials during tumor board meetings
- Designate a nurse to serve as a clinical trial coordinator who will facilitate the referral process when patients are eligible and willing to participate in a clinical trial

This data collection sheet is a resource from the ACCC educational initiative, Fostering Excellence in Care and Outcomes in Patients with Stage III/IV NSCLC.